| Abstract |
Objective To observe the effect of Shugan Jieyu Capsule combined with Qianlixin in patients with chronic obstructive pulmonary disease and depression. Methods A total of 97 patients with chronic obstructive pulmonary disease and depression were enrolled in our hospital. Randomized supportive therapy was given to both groups. 48 patients in the control group were given Deanxit oral therapy, and 49 patients in the observation group. Add Shugan Jieyu Capsule orally, compare serum norepinephrine (NE), dopamine (DA), serotonin (5-HT), immune function, vital capacity (VC), one second after treatment Specific vital capacity (FEV1/FVC), one second ratio predicted (FEV1%pred), Hamilton Depression Rating Scale (HAMD), COPD Symptom Assessment Score (CAT), clinical efficacy, and treatment safety. Results After treatment, the levels of DA, NE, 5-HT, CD3+, CD4+, CD4+/CD8+, FEV1% pred, VC, FEV1/FVC and total effective rate were higher in the observation group than in the control group, and the CD8+ level and the HAMD and CAT scores were low. In the control group (P<0.05)，There was no significant difference in TESS scores (P>0.05). Conclusion Shugan Jieyu Capsule combined with Deanxit can effectively eliminate depression and improve lung function in patients with chronic obstructive pulmonary disease and depression. The mechanism is related to the regulation of neurotransmitter levels and immune function.
|